Our mission is to advance the development of cell and gene therapies that are affordably priced and deliver superior efficacy, and to explore treatment regimens that help cancer patients achieve long-term remission.

Our vision is to join hands with clinical institutions in China and abroad to drive technological progress in cell and gene therapy. Leveraging multiple registered clinical trial resources within our collaborative network, we conduct CAR-T clinical research with numerous domestic medical institutions, continuously broadening the clinical settings in which our therapies can be applied, and steadily advancing toward the goals of higher safety, better tolerability, and long-term remission.

We have established a cross-border technical exchange network, forming a CAR-T technology exchange alliance with Nagoya University Hospital (Japan), Siriraj Hospital of Mahidol University (Thailand), and the National Research Center for Hematology (Russia). We regularly present our research findings at the Annual Meeting of the American Society of Hematology (ASH), sharing the data and practical experience gained through clinical exploration.

More than 6,000 genetic disorders have been identified worldwide. In China, an estimated 16.8 million people are affected by severe genetic deficiency diseases, yet only around 1% of patients have access to treatments capable of achieving long-term disease control. Much of the medication currently available relies on private donations, and clinical needs remain far from being met.

The company is deeply engaged in fourth-generation CAR-T technology and has built in a safety control mechanism that enables drug-inducible, controllable apoptosis. Current clinical exploration covers hematologic cancers (leukemia, lymphoma, multiple myeloma), brain tumors (neuroblastoma, glioma), and colorectal cancer, with continued expansion into further solid tumor indications. Our genetic disorder pipeline targets monogenic rare diseases including metachromatic leukodystrophy (MLD), adrenoleukodystrophy (ALD), hemophilia, thalassemia, and aplastic hematopoietic disorders. At the same time, we are refining our lentiviral vector processes and developing ready-to-use standardized vector products that simplify gene modification workflows at medical institutions, extending the reach of advanced therapies to benefit more patients.